期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

MKP-1对肿瘤耐药性的研究进展 被引量：2

Research progress on MKP-1 in tumor drug resistance
下载PDF
导出
摘要 肿瘤细胞对化疗药物的耐药性已成为肿瘤化疗的主要障碍,探索耐药性的产生机制,逆转肿瘤细胞的耐药性,是提高肿瘤化疗效果的关键。研究发现,丝裂原活化蛋白激酶磷酸酶-1(mitogen-activated protein kinase phosphatase-1,MKP-1)与多种肿瘤细胞的耐药性密切相关。MKP-1作为MAPKs的负调节子,对肿瘤耐药性的影响大多是通过MAPK信号通路介导的;同时,其又被MAPK家族成员ERK和p38反向调控。因此,研究MKP-1影响肿瘤耐药性的机制,探讨MKP-1与其他肿瘤耐药性相关信号通路的相互联系是将来肿瘤耐药性研究方向之一。 The main obstacle for chemotherapy is tumor drug resistance.Studying the mechanisms of drug resistance and reversing drug resistance is the key to improve the effectiveness of chemotherapy.It has been reported that MKP-1 plays an important role in tumor drug resistance.MKP-1,as a negative regulator of MAPKs,is involved in the MAPKs mediated drug resistance and is regulated by ERK and p38 signaling pathways.However,the relationship between MKP-1 and other drug resistance-related signaling pathways is not clear and requires further investigation.
作者 海燕 唐修文
机构地区 浙江大学医学院生物化学与遗传学系
出处 《浙江大学学报（医学版）》 CAS CSCD 北大核心 2012年第1期111-116,共6页 Journal of Zhejiang University(Medical Sciences)
基金 国家自然科学基金(30973555 31170743)
关键词 丝裂原活化蛋白激酶/代谢 丝裂原激活蛋白激酶类/代谢 抗药性 肿瘤 Mitogen-activated protein kinase 1/metabolism Mitogen-activated protein kinases/metabolism Drug resistance neoplasm
分类号 R730.5 [医药卫生—肿瘤]
  • 相关文献

参考文献29

  • 1WU G S.Role of mitogen-activated protein kinase phosphatases(MKPs) in cancer[J].Cancer and Metastasis Reviews,2007,26 (3-4),579-585.
  • 2HAAGENSON K K,WU G S.The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment[J].Cancer Metastasis Rev,2010,29:143-149.
  • 3KEYSE S M. Dual-specificity MAP kinase phosphatases (MKPs) and cancer[J].Cancer Metastasis Rev,2008,27:253-261.
  • 4HUTTER D,CHEN P,BARNES J,et al.Catalytic activation of mitogen-activated protein (MAP) kinase phosphatase-1 by binding to p38 MAP kinase:critical role of the p38 C-terminal domain in its negative regulation[J].Biochem J,2000,352(1):155-163.
  • 5SHI Y Y,SMALL G W,ORLOWSKI R Z.Proteasome inhibitors induce a p38 mitogenactivated protein kinase (MAPK)-dependent antiapoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer[J].Breast Cancer Res Treat,2006,100 (1):33-47.
  • 6WANG Z,XU J,ZHOU J Y,et al.Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance[J].Cancer Research,2006,66(17):8870-8877.
  • 7CHATFOPADHYAY S,MACHADO-PINILLA R,MANGUAN-GARCIA C,et al. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer[J].Oncogene,2006,25:3335-3345.
  • 8WU J J,BENNETT A M.Essential role for MAP kinase phosphatase-1 in stress-responsive MAP kinase and cell urvival signaling[J].J Biol Chem,2005,280:16461-16466.
  • 9ABRAMS M T,ROBERTSON N M,LITWACK G,et al.Evaluation of glucocorticoid sensitivity in 697 pre-B acute lymphoblastic leukemia cells after overexpression or silencing of MAP kinase phosphatase-1[J].J Cancer Res Clin Oncol,2005,131:347-354.
  • 10WANG J,ZHOU J Y,WU G S.ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells [J].Cancer Research,2007,67 (24):11933-11941.

二级参考文献35

  • 1Surh YJ. Cancer chemoprevention with dietary phytochemicals, Nat Rev Cancer, 2003, 3(10): 768-780
  • 2Pastan I, Gottesman M. Multiple-drug resistance in human cancer, N Engl J Med, 1987, 316(22): 1388-1393
  • 3Shibata T, Ohta T, Tong KI, et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligaseand promote malignancy, Proc Natl Acad Sci USA, 2008, 105(36): 13568-13573
  • 4Dinkova-Kostova AT, Holtzclaw WD, Cole RN, et al. Direct evidence that sulfhydryl groups of Keapl are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants, Proc Natl Acad Sci USA, 2002, 99(18): 11908-11913
  • 5Singh A, Misra V, Thimmulappa RK, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer, PLoS Med, 2006, 3(10): e420
  • 6Minerva RG, Kwak MK, Dolan PM, et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice, Proc Natl Acad Sci USA, 2001, 98(6): 3410-3415
  • 7Morimitsu Y, Nakagawa Y, Hayashi K, et al. A sulforaphane analogue that potently activates the Nrf2-dependent detoxification pathway, J Biol Chem, 2002, 277(5): 3456-3463
  • 8Lee JM, Calkins M J, Chan K, et al. Identification of the NF-E2- related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis, J Biol Chem, 2003, 278(14): 12029- 12038
  • 9Thimmulappa RK, Mai KH, Srisuma S, et al. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray, Cancer Res, 2002, 62(18): 5196-5203
  • 10Lee JS, Surh YJ. Nrf2 as a novel molecular target for chemoprevention, Cancer Lett, 2005, 224(2): 171-184

共引文献11

同被引文献24

  • 1Shevde LA, Das S, Clark DW, et al. Osteopontin: an effector and an effect of tumor metastasis[J]. Curr Mol Med, 2010, 10(1):71-81.
  • 2Briese J, Cheng S, Ezzat S, et al. Osteopontin ( OPN ) expression in thyroid carcinoma[J]. Anticancer Res, 2010, 30(5): 1681-1688.
  • 3Cui R, Takahashi F, Ohashi R, et al. Osteopontin is involved inthe formation of malignant pleural effusion in lung cancer[J]. Lung Cancer, 2009, 63(3):368-374.
  • 4Wang X, Chao L, Ma G, et al. Primary breast carcinoma: association of mammographic calcifications with osteopontin expression[J]. Radiology, 2010, 254(1):69-78.
  • 5Likui W, Hong W, Shuwen Z. Clinical significance of/he upregulated osteopontin mRNA expression in human colnrectal cancer[J]. J Gastrointest Surg, 2010, 14(1):74-81.
  • 6Lepage C, Cottet V, Chauvenet M, et al. Trends in the incidence and management of biliary tract cancer: a French population-based study[J]. J Hepatol, 2011, 54(2):306-310.
  • 7Eto M, Kodama S, Nomi N, et al. Clinical significance of elevated osteopontin levels in head and neck cancer patients[J]. Auris Nasus Larynx, 2007, 34(3):343-346.
  • 8Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies[J]. Clin Cancer Res, 2004, 10(1 Pt 1): 184-190.
  • 9Briese J, Cheng S, Ezzat S, et al. Osteopontin (OPN) expression in thyroid carcinoma[J]. Anticancer Res, 2010, 30(5): 1681-1688.
  • 10Chen RX, Xia YH, Cui JF, et al. Osteopontin, a single marker for predicting the prognosis of patients with tumor-node-metastasisstage I hepatoeellular carcinoma after surgical resection[J]. J Gastroenterol Hepatol, 2010, 25(8):1435-1442.

引证文献2

二级引证文献4

浙江大学学报（医学版）
2012年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部